SCHEMBL4207336

SCHEMBL4207336

CCc1cc(Br)ccc1S(=O)(=O)Nc1ccc(OC)c2c1OC[C@H](N(C)C)C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.46
QRFPR Q96P65 1/20 0.46
WDR5 P61964 3/20 0.39
BRD4 O60885 9/20 0.38
ACLY P53396 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
BRD1 O95696 1/20 0.38
BRPF1 P55201 1/20 0.38
BRPF3 Q9ULD4 1/20 0.38
GLA P06280 1/20 0.38
GHSR Q92847 1/20 0.37
MYC P01106 1/20 0.37
TSHR P16473 2/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4205802 0.90 WDR5 (0.48) HTR6QRFPRWDR5BRD4ACLY
SCHEMBL4206086 0.89 BRD4 (0.49) HTR6QRFPRWDR5BRD4ACLY
SCHEMBL4204347 0.88 HTR6 (0.47) HTR6QRFPRWDR5BRD4ACLY
SCHEMBL4205717 0.84 GHSR (0.43) HTR6QRFPRGHSRTSHRALDH1A1
SCHEMBL4207296 0.84 HTR6 (0.61) HTR6QRFPRWDR5BRD4ACLY
SCHEMBL4202583 0.83 HTR6 (0.42) HTR6QRFPRWDR5BRD4ACLY
SCHEMBL4196123 0.83 GHSR (0.47) HTR6QRFPRWDR5GHSRALDH1A1
SCHEMBL4967087 0.83 GHSR (0.47) HTR6QRFPRWDR5GHSRALDH1A1
SCHEMBL4201082 0.82 HTR6 (0.45) HTR6QRFPRBRD4ACLYTSHR
SCHEMBL4208508 0.82 HTR6 (0.49) HTR6QRFPRBRD4SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885WDR5 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.